NY-CELONIS
14.5.2024 08:01:35 CEST | Business Wire | Press release
Celonis, the global leader in Process Mining, announced today that it has been named a Leader in the Gartner Magic Quadrant for Process Mining Platforms for the second time since the category's inception last year. Celonis was evaluated and placed in the Leaders’ Quadrant, being positioned highest on the Ability to Execute axis and advancing to the furthest spot on the Completeness of Vision axis once again.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240513067064/en/
Celonis is a Leader in the 2024 Gartner Magic Quadrant for Process Mining Platforms, placed highest on the Ability to Execute and highest on Completeness of Vision. (Graphic: Business Wire)
“The pace of change keeps accelerating - new technologies keep emerging, customer expectations keep rising, and the need for greater efficiency keeps increasing. To succeed, organizations need solutions that help them address all these demands, and most importantly create meaningful value,” said Alex Rinke, co-CEO and co-founder of Celonis. “Celonis gives companies a common language for how their business runs and provides the context to enable technologies like AI and automation to become effective. For us, being named a Leader for the second consecutive year in the Gartner Magic Quadrant for Process Mining Platforms reinforces our commitment to make processes work for people, companies and the planet. We are proud to receive this recognition and will continue to build the future of process intelligence together with our customers, partners and fellow Celonauts who have embraced our vision and keep pushing process mining to realize its full potential.”
“Process mining has become an essential enterprise solution for adapting to an uncertain world and driving transformation at speed and scale,” said Daniel de Rooij, SVP Digital Transformation and CIO Hygiene at Reckitt, a global consumer products company with well-known brands such as Finish dishwasher tablets, Lysol disinfectant, and Nurofen painkillers. “With advancements like object-centric process mining and the Process Intelligence Graph, Celonis’ platform provides us with the unique process intelligence that we need to optimize IT operations, deliver value to the business faster, and drive disruptive innovation with emerging technologies like generative AI.”
Celonis enables customers to identify and capture hidden value, empower their people with actionable insights, and help them more effectively leverage technologies like AI and automation to optimize their processes. At the core of the Celonis Platform is the Process Intelligence Graph (PI Graph), an extensible digital twin of the business based on a standardized, object-centric data model. This twin is system-agnostic and without bias. The PI Graph adds business context to this process digital twin with out-of-the-box KPI definitions and improvement opportunities, such as how delivery blocks impact on-time delivery rate. Sitting at the heart of the Celonis platform, the PI Graph allows us to create capabilities that embed AI in ready-to-use solutions. For example, the Process Copilot chatbot turns natural language requests into process insights, and the AI-powered Duplicate Checker App helps keep customers from paying invoices twice. Using our Machine Learning (ML) Workbench customers and partners can create their own AI solutions in Celonis or feed data into their existing AI tools using our Intelligence API.
The platform also provides advanced process modeling functionality. In 2023, Celonis acquired Symbio, a provider of AI-driven Business Process Management (BPM) software. The integration of Symbio’s capabilities into the Celonis platform enables customers to not only mine their processes and identify value opportunities, but also design their ideal process using a modern, AI-assisted process modeling solution. Customers can also ensure their processes stay on the straight and narrow with the Process Adherence Manager and track the business impact of their process improvement work with the Transformation Hub.
Notes to editors
The 2024 Gartner Magic Quadrant on Process Mining Platforms is available here.
Find more information on Process Mining and the Celonis Process Intelligence Platform here.
Gartner, Magic Quadrant for Process Mining Platforms, Marc Kerremans, David Sudgen, Nick Duffy, 29 April 2024
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, and MAGIC QUADRANT is a registered trademark of Gartner, Inc. and/or its affiliates and are used herein with permission. All rights reserved.
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
About Celonis
Since 2011, Celonis has helped thousands of the world’s largest and most esteemed companies yield immediate cash impact, radically improve customer experience, and reduce carbon emissions. Its Process Intelligence platform uses industry-leading process mining technology and AI to present companies with a living digital twin of their end-to-end processes. For the first time, everyone in an organization has a common language for how the business runs, visibility into where value is hiding, and the ability to capture it. Celonis is headquartered in Munich, Germany and New York City, USA with more than 20 offices worldwide.
© 2024 Celonis SE. All rights reserved. Celonis and the Celonis “droplet” logo are trademarks or registered trademarks of Celonis SE in Germany and other jurisdictions. All other product and company names are trademarks or registered trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240513067064/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
